KLRK1 and lymphoma: Studies by Sentman and colleagues in mice demonstrated the efficacy of NKG2D-CAR T cells in eradicating established MM, lymphomas and ovarian cancers and inducing autologous immunity that protects against tumor rechallenge even after NKG2D-CAR T cells were no longer detectable (57).